About this document

Atorvastatin Pharmacogenomics by B23ES1018 is a document available to read on EtoBox.

This article reviews the pharmacogenomics of statins, focusing on their role in treating atherosclerotic cardiovascular disease and the adverse effects associated with their use. It highlights the significance of genetic polymorphisms, particularly SLCO1B1 521C, in predicting statin-related toxicity, especially statin-associated muscle symptoms (SAMS). The review emphasizes the need for personalized medicine approaches to optimize statin therapy and minimize adverse effects based on genetic profiles.

Author

B23ES1018

Language

EN